The elevated risk continued at 12 months, with hypotensive events rising from 13.6% to 14.3%
While no trials with GLP-1 RA monotherapy have specifically assessed the impact of these drugs on hard CVD outcomes in patients with established HF (Table 1), post-hoc analyses of early studies have demonstrated significant but inconsistent reductions in HF-related hospitalizations (HHF) in individuals with obesity and type 2 diabetes [33, 34]
Retatrutide Phase 3 data (TRIUMPH program) shows the highest weight loss numbers ever recorded in pharmacotherapy trials
By combining your medical history, symptoms, physical findings, lab results, and imaging studies, our providers can determine whether a hormonal imbalancesuch as PCOSis the likely cause of your missed period
However, damaged tissue reduces absorption reliability and may require higher doses to achieve the same effect